Background: Recently, we have shown anti-proliferative and pro-apoptotic effects of indicaxanthin associated with epigenetic modulation of the onco-suppressor p16INK4a in the human colon cancer cell line CACO2. In the present study, the epigenetic activity of indicaxanthin and the mechanisms involved were further investigated in other colorectal cancer cell lines. Methods: LOVO1, CACO2, HT29, HCT116, and DLD1 cells were used to evaluate the potential influence of consistent dietary concentrations of indicaxanthin on DNA methylation, and the epigenetic mechanisms involved were researched. Results: Indicaxanthin exhibited anti-proliferative activity in all cell lines but HT29, induced demethylation in the promoters of some methylation-silenced onco-suppressor genes involved in colorectal carcinogenesis (p16INK4a, GATA4, and ESR1), and left unchanged others which were basally hypermethylated (SFRP1 and HPP1). In apparent contrast, cell exposure to indicaxanthin increased DNMT gene expression, although indicaxanthin appeared to be an inhibitor of DNMT activity. Indicaxanthin also increased the expression of genes involved in DNA demethylation. Finally, an in silico molecular modelling approach suggested stable binding of indicaxanthin at the DNMT1 catalytic site. Conclusions: Our findings contribute to new knowledge in the field of phytochemicals and specifically suggest dietary indicaxanthin as a potential epigenetic agent to protect colon cells against tumoral alterations.

1.
Lipkin M, Reddy B, Newmark H, Lamprecht SA: Dietary factors in human colorectal cancer. Annu Rev Nutr 1999;19:545-586.
2.
Center MM, Jemal A, Smith RA, Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-378.
3.
GLOBOCAN Colorectal Cancer Data. 2012. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp.
4.
Martínez ME: Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Cancer Res 2005;166:177-211.
5.
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130:467S-471S.
6.
Szyf M: DNA methylation and demethylation as targets for anticancer therapy. Biochemistry 2005;70:533-549.
7.
Szyf M, Pakneshan P, Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol 2004;68:1187-1197.
8.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
9.
Hellebrekers DM, Lentjes MH, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, Smits KM, Akiyama Y, Yuasa Y, Sanduleanu S, Khalid-de Bakker CA, Jonkers D, Weijenberg MP, Louwagie J, van Criekinge W, Carvalho B, Meijer GA, Baylin SB, Herman JG, de Bruïne AP, van Engeland M: GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res 2009;15:3990-3997.
10.
Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-540.
11.
Gruenbaum Y, Naveh-Many T, Cedar H, Razin A: Sequence specificity of methylation in higher plant DNA. Nature 1981;292:860-862.
12.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-935.
13.
Stefanska B, Karlic H, Varga F, Fabianowska-Majewska K, Haslberger A: Epigenetic mechanisms in anti-cancer actions of bioactive food components - the implications in cancer prevention. Br J Pharmacol 2012;167:279-297.
14.
Nandakumar V, Vaid M, Katiyar SK: (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 2011;32:537-544.
15.
Kanner J, Harel S, Granit R: Betalains - a new class of dietary cationized antioxidants. J Agric Food Chem 2001;49:5178-5185.
16.
Butera D, Tesoriere L, Di Gaudio F, Bongiorno A, Allegra M, Pintaudi AM, Kohen R, Livrea MA: Antioxidant activities of Sicilian prickly pear (Opuntia ficus indica) fruit extracts and reducing properties of its betalains: betanin and indicaxanthin. J Agric Food Chem 2002;50:6895-6901.
17.
Tesoriere L, Allegra M, Butera D, Gentile C, Livrea MA: Kinetics of the lipoperoxyl radical-scavenging activity of indicaxanthin in solution and unilamellar liposomes. Free Radic Res 2007;41:226-233.
18.
Tesoriere L, Attanzio A, Allegra M, Gentile C, Livrea MA: Phytochemical indicaxanthin suppresses 7-ketocholesterol-induced THP-1 cell apoptosis by preventing cytosolic Ca2+ increase and oxidative stress. Br J Nutr 2013;110:230-240.
19.
Turco Liveri ML, Sciascia L, Allegra M, Tesoriere L, Livrea MA: Partition of indicaxanthin in membrane biomimetic systems. A kinetic and modeling approach. J Agric Food Chem 2009;57:10959-10963.
20.
Gentile C, Tesoriere L, Allegra M, Livrea MA, D'Alessio P: Antioxidant betalains from cactus pear (Opuntia ficus-indica) inhibit endothelial ICAM-1 expression. Ann NY Acad Sci 2004;1028:481-486.
21.
Tesoriere L, Attanzio A, Allegra M, Gentile C, Livrea MA: Indicaxanthin inhibits NADPH oxidase (NOX)-1 activation and NF-κB-dependent release of inflammatory mediators and prevents the increase of epithelial permeability in IL-1β-exposed Caco-2 cells. Br J Nutr 2014;111:415-423.
22.
Allegra M, Ianaro A, Tersigni M, Panza E, Tesoriere L, Livrea MA: Indicaxanthin from cactus pear fruit exerts anti-inflammatory effects in carrageenin-induced rat pleurisy. J Nutr 2014;144:185-192.
23.
Tesoriere L, Fazzari M, Angileri F, Gentile C, Livrea MA: In vitro digestion of betalainic foods. Stability and bioaccessibility of betaxanthins and betacyanins and antioxidative potential of food digesta. J Agric Food Chem 2008;56:10487-10492.
24.
Naselli F, Tesoriere L, Caradonna F, Bellavia D, Attanzio A, Gentile C, Livrea MA: Anti-proliferative and pro-apoptotic activity of whole extract and isolated indicaxanthin from Opuntia ficus-indica associated with re-activation of the onco-suppressor p16INK4a gene in human colorectal carcinoma (Caco-2) cells. Biochem Biophys Res Commun 2014;450:652-658.
25.
Belshaw NJ, Elliott GO, Foxall RJ, Dainty JR, Pal N, Coupe A, Garg D, Bradburn DM, Mathers JC, Johnson IT: Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008;99:136-142.
26.
Iacopetta B, Grieu F, Phillips M, Ruszkiewicz A, Moore J, Minamoto T, Kawakami K: Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci 2007;98:1454-1460.
27.
Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-2534.
28.
Prime 3.2. New York, Schrödinger LLC, 2013.
29.
Maestro 9.4. New York, Schrödinger LLC, 2013.
30.
Sherman W, Day T, Jacobson MP, Friesner RA, Farid R: Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534-553.
31.
Glide 5.9. New York, Schrödinger LLC, 2013.
32.
Almerico AM, Tutone M, Pantano L, Lauria A: Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence. Biochem Biophys Res Commun 2012;424:341-347.
33.
Almerico AM, Tutone M, Lauria A: In-silico screening of new potential Bcl-2/Bcl-xl inhibitors as apoptosis modulators. J Mol Model 2009;15:349-355.
34.
Desmond Molecular Dynamics System 3.6. New York, Shaw Research, Maestro-Schrödinger LLC, 2013.
35.
Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR: Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
36.
Kazazian HH Jr, Goodier J: LINE drive retrotransposition and genome instability. Cell 2002;110:277-280.
37.
Yoo J, Kim JH, Robertson KD, Medina-Franco JL: Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol 2012;87:219-247.
38.
Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, Hermus RJ, van den Brandt PA: Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol 2000;152:1081-1092.
39.
Gentile C, Perrone A, Attanzio A, Tesoriere L, Livrea MA: Sicilian pistachio (Pistacia vera L.) nut inhibits expression and release of inflammatory mediators and reverts the increase of paracellular permeability in IL-1β-exposed human intestinal epithelial cells. Eur J Nutr 2015;54:811-821.
40.
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362.
41.
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-88.
42.
Engelbrecht AM, Mattheyse M, Ellis B, Loos B, Thomas M, Smith R, Peters S, Smith C, Myburgh K: Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Lett 2007;258:144-153.
43.
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009;125:2332-2341.
44.
Berner C, Aumüller E, Gnauck A, Nestelberger M, Just A, Haslberger AG: Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Ann Nutr Metab 2010;57:183-189.
45.
Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA: Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 2005;4:1515-1520.
46.
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-7570.
47.
Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007;128:683-692.
48.
Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-3155.
49.
Choi SH, Heo K, Byun HM, An W, Lu W, Yang AS: Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res 2011;39:104-118.
50.
Lee WJ, Shim JY, Zhu BT: Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005;68:1018-1030.
51.
Chen T, Li E: Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol 2004;60:55-89.
52.
Wu SC, Zhang Y: Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010;11:607-620.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.